<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37720384</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-9361</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Therapeutic advances in infectious disease</Title><ISOAbbreviation>Ther Adv Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Long-COVID-19 clinical and health outcomes: an umbrella review.</ArticleTitle><Pagination><StartPage>20499361231198335</StartPage><MedlinePgn>20499361231198335</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20499361231198335</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/20499361231198335</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">A growing interest in long-term sequelae of COVID-19 has prompted several systematic literature reviews (SLRs) to evaluate long-COVID-19 effects. However, many of these reviews lack in-depth information on the timing, duration, and severity of these conditions.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Our aim was to synthesize both qualitative and quantitative evidence on prevalence and outcomes of long-term effect of COVID-19 through an umbrella review.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Umbrella review of relevant SLRs on long-COVID-19 in terms of prolonged symptoms and clinical conditions, and comprehensively synthesized the latest existing evidence.</AbstractText><AbstractText Label="DATA SOURCES AND METHODS" NlmCategory="UNASSIGNED">We systematically identified and appraised prior systematic reviews/meta-analyses using MEDLINE, Embase, and Cochrane database of systematic review from 2020 to 2021 following the preferred reporting items for systematic reviews and meta-analyses guidance. We summarized and categorized all relevant clinical symptoms and outcomes in adults with COVID-19 using the Medical Dictionary for Regulatory Activities System Organ Class (MedDRA SOC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified 967 systematic reviews/meta-analyses; 36 were retained for final data extraction. The most prevalent SOC were social circumstances (40%), blood and lymphatic system disorders (39%), and metabolism and nutrition disorder (38%). The most frequently reported SOC outcomes within each MedDRA category were poor quality of life (59%), wheezing and dyspnea (19-49%), fatigue (30-64%), chest pain (16%), decreased or loss of appetite (14-17%), abdominal discomfort or digestive disorder (12-18%), arthralgia with or without myalgia (16-24%), paresthesia (27%) and hair loss (14-25%), and hearing loss or tinnitus (15%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study confirmed a high prevalence of several long COVID-19 outcomes according to the MedDRA categories and indicated that the majority of evidence was rated as moderate to low.</AbstractText><AbstractText Label="REGISTRATION" NlmCategory="UNASSIGNED">The review was registered at PROSPERO (https://www.crd.york.ac.uk/prospero/) (CRD42022303557).</AbstractText><CopyrightInformation>&#xa9; The Author(s), 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0007-5513-1592</Identifier><AffiliationInfo><Affiliation>Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Takeda Development Center Americas, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Takeda Development Center Americas, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roque</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0169-3788</Identifier><AffiliationInfo><Affiliation>Research Unit for Inland Development, Polytechnic of Guarda (UDI-IPG), Guarda, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bam</LastName><ForeName>Rujuta A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Gilead Sciences Inc., Foster City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavares</LastName><ForeName>Ana B&#xe1;rbara Tadeu</ForeName><Initials>ABT</Initials><AffiliationInfo><Affiliation>Research Unit for Inland Development, Polytechnic of Guarda (UDI-IPG), Guarda, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gokhale</LastName><ForeName>Mugdha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ida</LastName><ForeName>Fidelia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CSL Behring LLC, King of Prussia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Jinnie Jiwon</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano Gabarro</LastName><ForeName>Montse</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bayer AG, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yiqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Infect Dis</MedlineTA><NlmUniqueID>101606715</NlmUniqueID><ISSNLinking>2049-9361</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MedDRA system organ classes</Keyword><Keyword MajorTopicYN="N">clinical outcomes</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">umbrella review</Keyword></KeywordList><CoiStatement>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DB and JX are employees of Takeda. FI is an employee of CSL Behring LLC. MSG is an employee of Bayer AG. MG is a full-time employee of Merck. HL and RAB are employees of Gilead Sciences Inc. ABTT was funded by the Grant CENTRO-04-3559-FSE-000162 within the European Social Fund (ESF). All other authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37720384</ArticleId><ArticleId IdType="pmc">PMC10501084</ArticleId><ArticleId IdType="doi">10.1177/20499361231198335</ArticleId><ArticleId IdType="pii">10.1177_20499361231198335</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr Clin Res Rev 2021; 15: 869&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9637465</ArticleId><ArticleId IdType="pubmed">36351871</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Z, Xu Y, Sun C, et al.. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol 2021; 54: 12&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227597</ArticleId><ArticleId IdType="pubmed">32425996</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, et al.. Characterising long COVID: a living systematic review. BMJ Glob Health 2021; 6: e005427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Health emergency dashboard, https://covid19.who.int/ (2021, accessed May 2022).</Citation></Reference><Reference><Citation>
Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK, https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (2021, accessed January 2023).</Citation></Reference><Reference><Citation>
Centers for Disease Control and Prevention: National Center for Health Statistics. Nearly one in five American adults who have had COVID-19 still have &#x201c;Long COVID.&#x201d;, https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm#print (2022, accessed August 2022).</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al.. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al.. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institutes of Health. NIH builds large nationwide study population of tens of thousands to support research on long-term effects of COVID-19, https://www.nih.gov/news-events/news-releases/nih-builds-large-nationwide-study-population-tens-thousands-support-research-long-term-effects-covid-19 (2021, accessed August 2022).</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao-Wong AC, Rump E, Moraleda T, et al.. Proposed terminology changes to facilitate the analysis of MedDRA&#xae;-Coded data. Ther Innov Regul Sci 2006; 40: 291&#x2013;303.</Citation></Reference><Reference><Citation>Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Online) 2017; 358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewin S, Booth A, Glenton C, et al.. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. Implement Sci 2018; 13(Suppl. 1): 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5791040</ArticleId><ArticleId IdType="pubmed">29384079</ArticleId></ArticleIdList></Reference><Reference><Citation>Amdal CD, Pe M, Falk RS, et al.. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. Qual Life Res 2021; 30: 3367&#x2013;3381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214069</ArticleId><ArticleId IdType="pubmed">34146226</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya JM, Rojas M, Salinas ML, et al.. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev 2021; 20: 102947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Beukes E, Ulep AJ, Eubank T, et al.. The impact of covid-19 and the pandemic on tinnitus: a systematic review. J Clin Med 2021; 10: 2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8268057</ArticleId><ArticleId IdType="pubmed">34201831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourmistrova NW, Solomon T, Braude P, et al.. Long-term effects of COVID-19 on mental health: a systematic review. J Affect Disord 2022; 299: 118&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758130</ArticleId><ArticleId IdType="pubmed">34798148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera Martimbianco AL, Pacheco RL, Bagattini &#xc2;M, et al.. Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review. Int J Clin Pract 2021; 75: e14357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236920</ArticleId><ArticleId IdType="pubmed">33977626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cares-Marambio K, Montenegro-Jim&#xe9;nez Y, Torres-Castro R, et al.. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis 2021; 18: 14799731211002240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7975482</ArticleId><ArticleId IdType="pubmed">33729021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, et al.. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun 2022; 101: 93&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Ettorre G, Gentilini Cacciola E, Santinelli L, et al.. Covid-19 sequelae in working age patients: a systematic review. J Med Virol 2022; 94: 858&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661973</ArticleId><ArticleId IdType="pubmed">34655247</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorri M, Mozafari Bazargany MH, Khodaparast Z, et al.. Psychological problems and reduced health-related quality of life in the COVID-19 survivors. J Affect Disord Rep 2021; 6: 100248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8495058</ArticleId><ArticleId IdType="pubmed">34642678</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Navarro-Santana M, G&#xf3;mez-Mayordomo V, et al.. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol 2021; 28: 3820&#x2013;3825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444899</ArticleId><ArticleId IdType="pubmed">34327787</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Palacios-Ce&#xf1;a D, G&#xf3;mez-Mayordomo V, et al.. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med 2021; 92: 55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Navarro-Santana M, Plaza-Manzano G, et al.. Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis. Pain 2022; 163: 1220&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pubmed">34561390</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al.. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021; 4: e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain N, Agarwala P, Iqbal K, et al.. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. J Med Virol 2022; 94: 1391&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">34931698</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal FM, Lam K, Sounderajah V, et al.. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine 2021; 36: 100899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8141371</ArticleId><ArticleId IdType="pubmed">34036253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings G, Monaghan A, Xue F, et al.. A systematic review of persistent symptoms and residual abnormal functioning following acute COVID-19: ongoing symptomatic phase vs. Post-covid-19 syndrome. J Clin Med 2021; 10: 5913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8708187</ArticleId><ArticleId IdType="pubmed">34945213</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, et al.. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract 2022; 39: 159&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Khraisat B, Toubasi A, AlZoubi L, et al.. Meta-analysis of prevalence: the psychological sequelae among COVID-19 survivors. Int J Psychiatr Clin Pract 2022; 26: 234&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">34709105</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q, Li J, Hu X, et al.. Follow-ups on persistent symptoms and pulmonary function among post-acute COVID-19 patients: a systematic review and meta-analysis. Front Med 2021; 8: 702635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8448290</ArticleId><ArticleId IdType="pubmed">34540862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al.. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11: 16144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, et al.. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)&#x2014;A systematic review and meta-analysis. J Med Virol 2022; 94: 253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open 2021; 4: e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrucco F, Zeppegno P, Baricich A, et al.. Long-lasting consequences of coronavirus disease 19 pneumonia: a systematic review. Minerva Med 2022; 113: 158&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">34856780</ArticleId></ArticleIdList></Reference><Reference><Citation>Poudel AN, Zhu S, Cooper N, et al.. Impact of Covid-19 on health-related quality of life of patients: a structured review. PLoS One 2021; 16: e0259164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553121</ArticleId><ArticleId IdType="pubmed">34710173</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S, Benzouak T, Gunpat S, et al.. Fatigue symptoms associated with COVID-19 in convalescent or recovered COVID-19 patients; a systematic review and meta-analysis. Ann Behav Med 2022; 56: 219&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574547</ArticleId><ArticleId IdType="pubmed">34665858</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud-Charest O, Lui LMW, Eskander S, et al.. Onset and frequency of depression in post-COVID-19 syndrome: a systematic review. J Psychiatr Res 2021; 144: 129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482840</ArticleId><ArticleId IdType="pubmed">34619491</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamanna F, Veronesi F, Martini L, et al.. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. A systematic review of the current data. Front Med 2021; 8: 653516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129035</ArticleId><ArticleId IdType="pubmed">34017846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ramirez DC, Normand K, Zhaoyun Y, et al.. Long-term impact of COVID-19: a systematic review of the literature and meta-analysis. Biomedicines 2021; 9: 900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389585</ArticleId><ArticleId IdType="pubmed">34440104</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler CX, Wyller VBB, Moss-Morris R, et al.. Long COVID and post-infective fatigue syndrome: a review. Open Forum Infect Dis 2021; 8: ofab440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496765</ArticleId><ArticleId IdType="pubmed">34631916</ArticleId></ArticleIdList></Reference><Reference><Citation>Schou TM, Joca S, Wegener G, et al.. Psychiatric and neuropsychiatric sequelae of COVID-19 &#x2013; A systematic review. Brain Behav Immun 2021; 97: 328&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363196</ArticleId><ArticleId IdType="pubmed">34339806</ArticleId></ArticleIdList></Reference><Reference><Citation>SeyedAlinaghi S, Afsahi AM, MohsseniPour M, et al.. Late complications of COVID-19; a systematic review of current evidence. Arch Acad Emerg Med 2021; 9: e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7927752</ArticleId><ArticleId IdType="pubmed">33681819</ArticleId></ArticleIdList></Reference><Reference><Citation>So M, Kabata H, Fukunaga K, et al.. Radiological and functional lung sequelae of COVID-19: systematic review and meta-analysis. BMC Pulm Med 2021; 21: 97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983097</ArticleId><ArticleId IdType="pubmed">33752639</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al.. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology 2021; 27: 328-337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687368</ArticleId><ArticleId IdType="pubmed">33262076</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderlind WM, Rabinovitz BB, Miao IY, et al.. A systematic review of neuropsychological and psychiatric sequalae of COVID-19: implications for treatment. Curr Opin Psychiatry 2021; 34: 420&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183238</ArticleId><ArticleId IdType="pubmed">34016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Wu Y, Xiong H, et al.. Persistence of symptoms after discharge of patients hospitalized due to COVID-19. Front Med (Lausanne) 2021; 8: 761314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8645792</ArticleId><ArticleId IdType="pubmed">34881263</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghaei A, Zhang R, Taylor S, et al.. Impact of COVID-19 symptoms on social aspects of life among female long haulers: a qualitative study. Res Sq. Epub ahead of print Feburary 2022. DOI: 10.21203/rs.3.rs-1285284/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1285284/v1.</ArticleId></ArticleIdList></Reference><Reference><Citation>Saladino V, Algeri D, Auriemma V. The psychological and social impact of Covid-19: new perspectives of well-being. Front Psychol 2020; 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561673</ArticleId><ArticleId IdType="pubmed">33132986</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, et al.. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 2021; 20: 172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol 2017; 29: 401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5890889</ArticleId><ArticleId IdType="pubmed">28541437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, et al.. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology 2022; 163: 495&#x2013;506.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, Jia M, Sun Y, et al.. One-year temporal change in prevalence and characteristic of long COVID: a systematic review and meta-analysis. Value Health 2023; 26: 934&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">36436792</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al.. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021; 4: e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Deng J, Liu Q, et al.. Long-term consequences of COVID-19 at 6 months and above: a systematic review and meta-analysis. Int J Environ Res Public Health 2022; 19: 6865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9180091</ArticleId><ArticleId IdType="pubmed">35682448</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 2018; 21: 95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10270421</ArticleId><ArticleId IdType="pubmed">30006442</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>